| Trial ID: | L1057 |
| Source ID: | NCT00337935
|
| Associated Drug: |
Epoetin Alfa
|
| Title: |
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00337935/results
|
| Conditions: |
Renal Failure , Chronic|Anemia
|
| Interventions: |
DRUG: Epoetin Alfa|OTHER: Standard of care
|
| Outcome Measures: |
Primary: Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks), Week 0 to Week 26 | Secondary: The Number of Patients Achieved a Hemoglobin Response., Hemoglobin reponse was defined as 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL, Week 0 to Week 26|Time to Hemoglobin Response, Time to hemoglobin reponse was defined as the time between individual treatment start date and the first of 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL. Note: Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment., Week 0 to Week 26
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Collaborators: Ortho Biotech Clinical Affairs, L.L.C.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
157
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-07
|
| Completion Date: |
2009-07
|
| Results First Posted: |
2013-05-13
|
| Last Update Posted: |
2013-05-13
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00337935
|
